💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tinzaparin Sodium

CHEMBL1201414 Phase 4 معتمد Oligosaccharide
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Tinzaparin sodium is a low molecular weight heparin (LMWH) derived by enzymatic depolymerization of unfractionated heparin that primarily inhibits factor Xa through antithrombin III, with lesser anti-IIa (thrombin) activity, providing predictable anticoagulation with subcutaneous administration. It is used for the prevention and treatment of deep vein thrombosis, pulmonary embolism, and anticoagulation in certain cancer patients with venous thromboembolism. Its predictable pharmacokinetics allow once-daily dosing without routine monitoring in most patients.

المجالات العلاجية

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Stroke Deep Vein Thrombosis / Pulmonary Embolism Obesity Lymphoma Hypertension Breast Cancer Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

Tinzaparin sodium is a low molecular weight heparin (LMWH) derived by enzymatic depolymerization of unfractionated heparin that primarily inhibits factor Xa through antithrombin III, with lesser anti-IIa (thrombin) activity, providing predictable anticoagulation with subcutaneous administration. It is used for the prevention and treatment of deep vein thrombosis, pulmonary embolism, and anticoagulation in certain cancer patients with venous thromboembolism. Its predictable pharmacokinetics allow once-daily dosing without routine monitoring in most patients.

Yes, Tinzaparin Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Oligosaccharide.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201414. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.